CHICAGO—At the Plenary Session of ASCO Maha Hussain MD, FACP of the University of Michigan in Ann Arbor presented results from a long-term, multicenter Phase III international clinical trial comparing two common therapies for men with hormone-sensitive metastatic prostate cancer. Afterwards she talked with Peter Goodwin.
LISTEN
[audio:https://www.audiomedica.com/podcasting/news/120610MahaHussainINTERVIEWLoRes.mp3]
Audio Journal of Oncology Podcast Esophageal Cancer Prevented By Proton Pump Inhibitor Plus Aspirin Play Episode Pause Episode Mute/Unmute Episode...
AudioMedica News ASCO 2012 ANNUAL MEETING: Targeted Drug Afatinib Delays Progression of Advanced Lung Cancers, Particularly Those With Specific...
Volker Diehl George Canellos Hodgkin’s Disease: 10-Year Results Show Further Benefit From Escalated BEACOPP Therapy REFERENCE: Abstract 8015...
Christian Manegold Roy Herbst More Support for Bevacizumab in Advanced Lung Cancer REFERENCE: Abstract LBA7514, ASCO Annual Meeting Chicago June 1-5...
Christiane Kuhl Julie Gralow MRI Better Than Mammography for Detecting High-Grade Ductal Carcinoma In Situ? REFERENCE: 1504, ASCO Annual Meeting...
Aimery de Gramont Robert Mayer MOSAIC Study Six Year Results: Adjuvant Oxaliplatin Adds Survival Advantage for Patients with Stage III Colorectal...
